Intravenous Immunoglobulin Market

Intravenous Immunoglobulin (IVIG) Market (Indication - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura (ITP), Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy (MMN), Kawasaki Disease, Hypogammaglobulinemia, and Chronic Lymphocytic Leukemia; End User - Hospitals, Clinics, and Home Care) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • Rep Id : TMRGL1930
  • Published On : Apr 2018
  • No. of Pages : 155
  • Category : Pharmaceutical

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map

Section 4 Market Overview
4.1 Indication Overview
4.2 Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3 Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators

Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
      5.2.1 Rise in prevalence of autoimmune disorders
      5.2.2 Increase in global geriatric population
      5.2.3 Growing usage in off-label indications
      5.2.4 Improved technology for production and purification methods
      5.2.5 Favorable government initiatives and approvals
      5.2.6 Increase in health care spending & improving health care infrastructure
      5.2.7 Rise in incidence of hematological, neurological disorders
5.3 Restraints
      5.3.1 High cost of treatment
      5.3.2 Chronic side effects
      5.3.3 Supply demand gaps
      5.3.4 Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5 Opportunities
      5.5.1 Application in newer indications
      5.5.2 Increasing global plasma yield to offer significant opportunities to new entrants
5.6 Key Trends
5.7 Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
5.8 Value Chain Analysis
5.9 Intravenous Immunoglobulin (IVIG) Market Outlook

Section 6 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1 Key Findings
6.2 Introduction
6.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication 
      6.4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      6.4.2 Primary Humoral Immunodeficiency 
      6.4.3 Idiopathic Thrombocytopenic Purpura (ITP)
      6.4.4 Guillain-Barre Syndrome
      6.4.5 Myasthenia Gravis
      6.4.6 Multifocal Motor Neuropathy (MMN)
      6.4.7 Kawasaki Disease
      6.4.8 Hypogammaglobulinemia
      6.4.9 Chronic Lymphocytic Leukemia
      6.4.10 Others
6.5 Market Attractiveness Analysis, by Indication
6.6 Key Trends

Section 7 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1 Key Findings
7.2 Introduction
7.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
      7.4.1 Hospitals
      7.4.2 Clinics
      7.4.3 Home Care
7.5 Market Attractiveness Analysis, by End-user
7.6 Key Trends

Section 8 Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1 Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3 Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4 Market Attractiveness Analysis, by Region

Section 9 North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1 Key Findings
9.2 Market Overview
9.3 Market Analysis, by Indication      
      9.3.1 Market Value Share Analysis, by Indication
      9.3.2 Market Size (US$ Mn) Forecast, by Indication
               9.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               9.3.2.2 Primary Humoral Immunodeficiency 
               9.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               9.3.2.4 Guillain-Barre Syndrome
               9.3.2.5 Myasthenia Gravis
               9.3.2.6 Multifocal Motor Neuropathy (MMN)
               9.3.2.7 Kawasaki Disease
               9.3.2.8 Hypogammaglobulinemia
               9.3.2.9 Chronic Lymphocytic Leukemia
               9.3.2.10 Others
9.4 Market Analysis, by End-user
      9.4.1 Market Value Share Analysis, by End-user
      9.4.2 Market Size (US$ Mn) Forecast, by End-user
               9.4.2.1 Hospitals
               9.4.2.2 Clinics
               9.4.2.3 Home Care
9.5 Market Analysis, by Country
      9.5.1 Market Value Share Analysis, by Country
      9.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               9.5.2.1 U.S.
               9.5.2.2 Canada
9.6 Market Attractiveness Analysis
      9.6.1 by Indication 
      9.6.2 by End-user
      9.6.3 by Country

Section 10 Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1 Key Findings
10.2 Market Overview
10.3 Market Analysis, by Indication
      10.3.1 Market Value Share Analysis, by Indication
      10.3.2 Market Size (US$ Mn) Forecast, by Indication
               10.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               10.3.2.2 Primary Humoral Immunodeficiency 
               10.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               10.3.2.4 Guillain-Barre Syndrome
               10.3.2.5 Myasthenia Gravis
               10.3.2.6 Multifocal Motor Neuropathy (MMN)
               10.3.2.7 Kawasaki Disease
               10.3.2.8 Hypogammaglobulinemia
               10.3.2.9 Chronic Lymphocytic Leukemia
               10.3.2.10 Others
10.4 Market Analysis, by End-user
      10.4.1 Market Value Share Analysis, by End-user
      10.4.2 Market Size (US$ Mn) Forecast, by End-user
               10.4.2.1 Hospitals
               10.4.2.2 Clinics
               10.4.2.3 Home Care
10.5 Market Analysis, by Country
      10.5.1 Market Value Share Analysis, by Country
      10.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               10.5.2.1 U.K.
               10.5.2.2 Germany
               10.5.2.3 France
               10.5.2.4 Spain
               10.5.2.5 Italy
               10.5.2.6 Rest of Europe
10.6 Market Attractiveness Analysis
      10.6.1 by Indication 
      10.6.2 by End-user
      10.6.3 by Country

Section 11 Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1 Key Findings
11.2 Market Overview
11.3 Market Analysis, by Indication
      11.3.1 Market Value Share Analysis, by Indication
      11.3.2 Market Size (US$ Mn) Forecast, by Indication
               11.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               11.3.2.2 Primary Humoral Immunodeficiency 
               11.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               11.3.2.4 Guillain-Barre Syndrome
               11.3.2.5 Myasthenia Gravis
               11.3.2.6 Multifocal Motor Neuropathy (MMN)
               11.3.2.7 Kawasaki Disease
               11.3.2.8 Hypogammaglobulinemia
               11.3.2.9 Chronic Lymphocytic Leukemia
               11.3.2.10 Others
11.4 Market Analysis, by End-user
      11.4.1 Market Value Share Analysis, by End-user
      11.4.2 Market Size (US$ Mn) Forecast, by End-user
               11.4.2.1 Hospitals
               11.4.2.2 Clinics
               11.4.2.3 Home Care
11.5 Market Analysis, by Country
      11.5.1 Market Value Share Analysis, by Country
      11.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               11.5.2.1 China
               11.5.2.2 Japan
               11.5.2.3 Australia
               11.5.2.4 India
               11.5.2.5 Rest of Asia Pacific
11.6 Market Attractiveness Analysis
      11.6.1 by Indication 
      11.6.2 by End-user
      11.6.3 by Country

Section 12 Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1 Key Findings
12.2 Market Overview
12.3 Market Analysis, by Indication
      12.3.1 Market Value Share Analysis, by Indication
      12.3.2 Market Size (US$ Mn) Forecast, by Indication
               12.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               12.3.2.2 Primary Humoral Immunodeficiency 
               12.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               12.3.2.4 Guillain-Barre Syndrome
               12.3.2.5 Myasthenia Gravis
               12.3.2.6 Multifocal Motor Neuropathy (MMN)
               12.3.2.7 Kawasaki Disease
               12.3.2.8 Hypogammaglobulinemia
               12.3.2.9 Chronic Lymphocytic Leukemia
               12.3.2.10 Others
12.4 Market Analysis, by End-user
      12.4.1 Market Value Share Analysis, by End-user
      12.4.2 Market Size (US$ Mn) Forecast, by End-user
               12.4.2.1 Hospitals
               12.4.2.2 Clinics
               12.4.2.3 Home Care
               12.5 Market Analysis, by Country
      12.5.1 Market Value Share Analysis, by Country
      12.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               12.5.2.1 Brazil
               12.5.2.2 Mexico
               12.5.2.3 Rest of LATAM
12.6 Market Attractiveness Analysis
      12.6.1 by Indication 
      12.6.2 by End-user
      12.6.3 by Country

Section 13 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1 Key Findings
13.2 Market Overview
13.3 Market Analysis, by Indication
      13.3.1 Market Value Share Analysis, by Indication
      13.3.2 Market Size (US$ Mn) Forecast, by Indication
               13.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               13.3.2.2 Primary Humoral Immunodeficiency 
               13.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               13.3.2.4 Guillain-Barre Syndrome
               13.3.2.5 Myasthenia Gravis
               13.3.2.6 Multifocal Motor Neuropathy (MMN)
               13.3.2.7 Kawasaki Disease
               13.3.2.8 Hypogammaglobulinemia
               13.3.2.9 Chronic Lymphocytic Leukemia
               13.3.2.10 Others
13.4 Market Analysis, by End-user
      13.4.1 Market Value Share Analysis, by End-user
      13.4.2 Market Size (US$ Mn) Forecast, by End-user
               13.4.2.1 Hospitals
               13.4.2.2 Clinics
               13.4.2.3 Home Care
13.5 Market Analysis, by Country
      13.5.1 Market Value Share Analysis, by Country
      13.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               13.5.2.1 South Africa
               13.5.2.2 Saudi Arabia
               13.5.2.3 Rest of MEA
13.6 Market Attractiveness Analysis
      13.6.1 by Indication 
      13.6.2 by End-user
      13.6.3 by Country

Section 14 Company Profiles
14.1 Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)
14.2 Competition Matrix
14.3 Company Profiles
      14.3.1 Baxalta Incorporated
               14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.1.2 Financial Overview
               14.3.1.3 Product Portfolio
               14.3.1.4 SWOT Analysis
               14.3.1.5 Strategic Overview
      14.3.2 Biotest AG
               14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.2.2 Financial Overview
               14.3.2.3 Product Portfolio
               14.3.2.4 SWOT Analysis
               14.3.2.5 Strategic Overview
      14.3.3 China Biologic Products, Inc.
               14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.3.2 Financial Overview
               14.3.3.3 Product Portfolio
               14.3.3.4 SWOT Analysis
               14.3.3.5 Strategic Overview
      14.3.4 CSL Behring LLC
               14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.4.2 Financial Overview
               14.3.4.3 Product Portfolio
               14.3.4.4 SWOT Analysis
               14.3.4.5 Strategic Overview
      14.3.5 Grifols S.A.
               14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.5.2 Financial Overview
               14.3.5.3 Product Portfolio
               14.3.5.4 SWOT Analysis
               14.3.5.5 Strategic Overview
      14.3.6 Kedrion S.p.A.
               14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.6.2 Financial Overview
               14.3.6.3 Product Portfolio
               14.3.6.4 SWOT Analysis
               14.3.6.5 Strategic Overview
      14.3.7 LFB Biomedicaments S.A.
               14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.7.2 Financial Overview
               14.3.7.3 Product Portfolio
               14.3.7.4 SWOT Analysis
               14.3.7.5 Strategic Overview
      14.3.8 Octapharma AG
               14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.8.2 Financial Overview
               14.3.8.3 Product Portfolio
               14.3.8.4 SWOT Analysis
               14.3.8.5 Strategic Overview
      14.3.9 Sanquin Plasma Products B.V.
               14.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.9.2 Financial Overview
               14.3.9.3 Product Portfolio
               14.3.9.4 SWOT Analysis
               14.3.9.5 Strategic Overview

List of Tables

Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 07: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 08: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 09: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 10: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 11: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 12: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 13: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2014–2024
Table 14: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 15: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 16: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2014–2024
Table 17: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 18: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Figures

Figure 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2016 and 2024
Figure 03: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2014–2024
Figure 04: Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2014–2024
Figure 05: Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2014–2024
Figure 06: Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 07: Global Myasthenia Gravis Market Revenue, US$ Mn, 2014–2024
Figure 08: Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2014–2024
Figure 09: Global Kawasaki Disease Market Revenue, US$ Mn, 2014–2024
Figure 10: Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2014–2024
Figure 11: Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2014–2024
Figure 12: Global Other Indications Market Revenue, US$ Mn, 2014–2024
Figure 13: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
Figure 14: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2016 and 2024
Figure 15: Global Hospitals Market Revenue, US$ Mn, 
Figure 16: Global Clinics Market Revenue, US$ Mn,
Figure 17: Global home care Market Revenue, US$ Mn, 2014–2024
Figure 18: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
Figure 19: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2016 and 2024
Figure 20: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
Figure 21: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
Figure 22: North America Market Attractiveness Analysis, by Country
Figure 23: North America Market Value Share Analysis, by Indication, 2016 and 2024
Figure 24: North America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 25: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 26: North America Market Attractiveness Analysis, by Indication 
Figure 27: North America Market Attractiveness Analysis, by End-user
Figure 28: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
Figure 29: Europe Market Attractiveness Analysis, by Country
Figure 30: Europe Market Value Share Analysis, by Indication, 2016 and 2024
Figure 31: Europe Market Value Share Analysis, by End-user, 2016 and 2024
Figure 32: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: Europe Market Attractiveness Analysis, by Indication
Figure 34: Europe Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 36: Asia Pacific Market Attractiveness Analysis, by Country
Figure 37: Asia Pacific Market Value Share Analysis, by Indication, 2016 and 2024
Figure 38: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
Figure 39: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 40: Asia Pacific Market Attractiveness Analysis, by Indication
Figure 41: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 42: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 43: Latin America Market Attractiveness Analysis, by Country
Figure 44: Latin America Market Value Share Analysis, by Indication, 2016 and 2024
Figure 45: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 46: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 47: Latin America Market Attractiveness Analysis, by Indication
Figure 48: Latin America Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 50: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 51: Middle East & Africa Market Value Share Analysis, by Indication, 2016 and 2024
Figure 52: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
Figure 53: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 54: Middle East & Africa Market Attractiveness Analysis, by Indication
Figure 55: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 56: Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)

.